Skye Bioscience, Inc.
SKYEDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How SKYE's past catalysts played out
Nimacimab injection
Obesity
SBI-100 Ophthalmic Emulsion, 0.5%
Primary Open Angle Glaucoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nimacimab injection | Phase 2 | Obesity | - | - |
SBI-100 Ophthalmic Emulsion, 0.5% | Phase 2 | Primary Open Angle Glaucoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Skye Bioscience, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Skye Bioscience, Inc.'s (SKYE) pipeline across Phase 2. Its lead program is Nimacimab injection (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Skye Bioscience, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Skye Bioscience, Inc. (SKYE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SKYE biotech catalysts?→
Add SKYE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Skye Bioscience, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.